Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Gynecol Oncol. 2017 Nov 23;148(1):213–221. doi: 10.1016/j.ygyno.2017.11.020

Figure 3.

Figure 3

Figure 3

Figure 3

Figure 3

Figure 3

Figure 3

Pathologic correlates of molecular/genetic alterations. a) Homologous recombination-deficient high-grade serous carcinoma exhibiting solid, endometrioid, and transitional cell carcinoma (SET)-like morphology. b) Endometrioid adenocarcinoma with mucinous differentiation, which is more frequently associated with KRAS mutations. c–f) BRAF-mutated serous borderline tumor showing complex papillary architecture (c), a subpopulation of cells with abundant eosinophilic (pink) cytoplasm (d, e). Cells bud from the epithelial surface, leading to the appearance of individual cells and clusters of detached cells (e). Immunohistochemistry for BRAF VE1 shows overexpression, which correlates with the presence of V600E BRAF mutation (f).